Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
These findings suggest that clone size at PNH onset may serve as a prognostic factor for disease burden and MAVEs/TEs, aiding in clinical decision-making about treatment initiation or maintenance. In ...
In his closing thoughts, Dr De Castro provides a final overview of the ASH conference, highlighting updates in PNH treatment. Carlos M. De Castro, MD: I’d love to say we need more studies, studying ...
Healio spoke with Marcel P. Devetten, MD, associate professor of oncology and hematology at University of Nebraska Medical Center, about multidisciplinary care in paroxysmal nocturnal hemoglobinuria ...
Carlos M. De Castro, MD, highlights the phase III Apply-PNH study presented at ASH 2022. Carlos M. De Castro, MD: In PNH [paroxysmal nocturnal hemoglobinuria], the needs are 2-fold. Over the past 20 ...
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease that can cause fatigue due to anemia. PNH is closely associated with fatigue due to a loss of red blood cells, leading to anemia. This ...
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease in which the immune system breaks apart the red blood cells (RBCs) in the body. The medical term for this premature rupture of RBCs is ...
Ilene Weitz, MD, discusses research on several new therapies for paroxysmal nocturnal hemoglobinuria (PNH) with promising clinical impact presented at ASH 2024. The APPLY-PNH and APPOINT-PNH studies ...
The US Food and Drug Administration (FDA) recently approved two biosimilars to Soliris for the treatment of two rare diseases — paroxysmal nocturnal hemoglobinuria (PNH), a debilitating and ...
Please provide your email address to receive an email when new articles are posted on . Crovalimab provided disease control and proved noninferior to a current standard-of-care treatment for certain ...
The FDA approved the complement C5 inhibitor crovalimab (Piasky) for treating paroxysmal nocturnal hemoglobinuria (PNH), a rare but life-threatening blood disease. Indicated for PNH in adults and ...
A acquired deficiency in the PIGA gene alters red blood cells. Paroxysmal nocturnal hemoglobinuria results when these altered cells replicate. Medications can stop the breakdown of red blood cells and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results